文献速递妇科

重度经治的BRCA1/2突变卵巢癌患者的化疗与PARP抑制剂应用

Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
PubMed 文献 · Gynecol Oncol · 2018-12-12

该研究纳入2006至2016年西班牙4个癌症中心的135例胚系和/或体细胞BRCA1/2突变卵巢癌患者,分析重度经治(≥3线化疗)患者的化疗疗效。结果显示,在铂敏感背景下,含铂化疗联合PARP抑制剂、含铂化疗或PARP抑制剂的中位TTP均优于非含铂化疗;原发无铂间期>12个月及暴露于含铂化疗和PARP抑制剂与预后改善相关。

要点

  • 重度经治BRCA1/2突变卵巢癌仍显示化疗敏感性,包括非含铂化疗选择。
  • 铂敏感背景下,含铂化疗+PARP抑制剂、含铂化疗或PARP抑制剂的中位TTP均优于非含铂化疗。
  • 原发无铂间期>12个月及暴露于含铂化疗和PARP抑制剂与预后改善相关。

核心结论

  • 重度经治的胚系和/或体细胞BRCA1/2突变卵巢癌显示化疗敏感性,包括非含铂化疗选择。
  • 原发无铂间期>12个月及暴露于含铂化疗和PARP抑制剂与重度经治患者的预后改善相关。

研究设计与样本

  • 研究纳入2006至2016年西班牙4个癌症中心的胚系和/或体细胞BRCA1/2突变卵巢癌患者。
  • 共识别135例患者,其中体细胞BRCA1/2突变占6%。
  • 采用Kaplan-Meier法和Cox模型计算总生存期和至进展时间。

主要发现

  • 中位化疗线数为2线(范围1-7线)。
  • BRCA1与BRCA2突变携带者的6年OS率分别为69.4%和71%(p=0.98)。
  • 57例(42%)患者接受≥3线化疗(范围3-7线),共涵盖155次治疗。
  • 第2线以后所有治疗线的中位总体TTP为10.2个月(95%CI 8.4-11.9个月)。
  • 铂敏感背景下,含铂化疗联合PARP抑制剂(17.1个月)、含铂化疗(12.6个月)或PARP抑制剂(12.4个月)的TTP均优于非含铂化疗(4.9个月;所有比较p<0.001);铂耐药背景下这些TTP差异无统计学显著性。

关键数值与推荐

  • 多因素模型证实原发无铂间期>12个月及暴露于含铂化疗和PARP抑制剂与预后改善相关。
  • PARP抑制剂暴露未损害第2次复发后后续化疗的获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The hallmarks of germline(g) and/or somatic(s) BRCA1/2 mutation ovarian cancer (BMOC) patients are increased sensitivity to platinum-based chemotherapy (PCT) and PARP inhibitors (PARPi). There is little information on the effectiveness of chemotherapy in heavily pretreated (≥3 CT lines) g/sBMOC patients. METHODS: g/sBMOC patients who received CT from 2006 to 2016 at 4 cancer centers in Spain were selected. Overall survival (OS) and time to progression (TTP) were calculated with Kaplan Meier and Cox models. RESULTS: 135 g/sBMOC patients were identified (6% sBRCA1/2 mutations). The median number of chemotherapy lines was 2 (1-7). The 6-years OS rate was 69.4% and 71% in BRCA1 or BRCA2 mutation carriers (p = 0.98). A total of 57 (42%) patients had ≥3 CT lines (3-7), which encompassed a total of 155 treatments. The median overall TTP across all treatment lines beyond 2nd line was 10.2 months (CI 95% 8.4-11.9 months). In the platinum-sensitive setting, TTP was improved with PCT plus PARPi (17.1 m), PCT (12.6 m) or PARPi (12.4 m) versus non-PCT (4.9 m; p < 0.001 all comparisons). In the platinum-resistant setting, these differences in TTP were not statistically significant. A multivariate model confirmed that primary platinum-free interval (PFI) > 12 months and exposure to PCT and PARPi associated with improved outcomes. PARPi exposure did not compromise benefit of subsequent CT beyond 2nd relapse. CONCLUSIONS: Heavily pretreated g/sBMOC demonstrated CT sensitivity, including for non-PCT choices. Primary platinum-free interval (PFI) >12 months and exposure to both platinum-based chemotherapy and PARPi associate with improved prognosis in heavily pretreated g/sBMOC patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Rodriguez-Freixinos V, Fariñas-Madrid L, Gil-Martin M, et al. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients. Gynecol Oncol. 2018. PMID: 30551885. doi:10.1016/j.ygyno.2018.11.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。